Price
Target price
€56.12
€56.12
-1.310%
-0.74
-1.310%
€67.72
28.10.25 / Tradegate
WKN: A0DLHS / Symbol: HALO / Name: Halozyme / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Halozyme Therapeutics Inc. Stock
We can see a decrease in the price for Halozyme Therapeutics Inc.. Compared to yesterday it has lost -€0.740 (-1.310%).
With 19 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 67 € there is a slightly positive potential of 19.39% for Halozyme Therapeutics Inc. compared to the current price of 56.12 €.
Our community identified positive and negative aspects for Halozyme Therapeutics Inc. stock for the coming years. 2 users see the criterium "Worthwhile Investment for the next years" as a plus for the Halozyme Therapeutics Inc. stock. On the other hand our users think that "Expected dividend yield" could be a problem in the future.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | -1.310% | -2.637% | -10.949% | 20.249% | 22.801% | 16.010% | 131.423% |
| Ironwood Pharmaceuticals | -1.420% | 6.923% | 19.828% | -63.613% | -66.905% | -87.137% | -82.733% |
| Novocure Ltd | -0.170% | -5.911% | 4.182% | -25.463% | -60.646% | -83.708% | -88.178% |
| Iovance Biotherapeutics Inc. | -3.700% | -3.524% | 4.738% | -81.544% | -72.728% | -79.296% | -93.771% |
Comments
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its price target lowered by analysts at Morgan Stanley from $80.00 to $79.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
News
Halozyme (HALO) Q2 EPS Jumps 69%
Halozyme Therapeutics (NASDAQ:HALO), a biotechnology company specializing in drug delivery innovations, released its second-quarter 2025 results on August 5, 2025. The quarter’s headline is
